查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014954

男性不孕症市場：2026-2032年全球市場預測（依治療方法、產品類型、最終用戶及通路分類）

Male Infertility Market by Treatment Type, Product Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年男性不孕症治療市場價值44.2億美元，預計到2026年將成長至47.9億美元，複合年成長率為9.45%，到2032年將達到83.3億美元。

主要市場統計數據
基準年 2025 44.2億美元
預計年份：2026年 47.9億美元
預測年份 2032 83.3億美元
複合年成長率 (%) 9.45%

全面概述了影響男性不孕症治療的臨床、技術和政策方面的變化，以及不同醫療保健環境下的行業應對措施。

男性不孕症已從一個小眾的臨床問題演變為生殖醫學、診斷學、醫療設備工程和公共衛生政策交叉領域的跨學科議題。檢測技術的進步、對遺傳和內分泌因素更深入的了解以及患者意識的提高，使得男性不孕症成為生育治療過程中的核心考量。隨著臨床醫生和研究人員不斷完善診斷標準和治療方法，行業相關人員也在重新審視其業務組合，以滿足當前的臨床需求並兼顧長期的生殖健康目標。

技術進步、以患者為中心的照護模式以及以診斷主導的路徑如何重塑男性不孕症的臨床實踐和商業策略？

由於技術進步、患者期望的改變以及診斷與治療的融合，男性不孕症治療領域正經歷著變革性的轉變。更便捷的基因檢測和更先進的診斷技術，包括高解析度精液分析，正在重新定義診斷流程，並實現個人化治療。同時，輔助生殖技術的改進，例如卵胞漿內單一精子注射（ICSI）和靶向精子獲取技術，也為存在嚴重男性因素不孕症的夫妻提供了更多選擇。

評估美國於 2025 年對生殖醫學領域醫療設備、診斷和治療產品分銷徵收關稅的累積營運和供應鏈影響。

美國於2025年引入並實施關稅，這給支持生殖技術的全球供應鏈帶來了明顯的摩擦，影響到製造商、經銷商和臨床服務提供者。離心機、培養箱和精密顯微鏡等專用設備的進口成本上升，可能會使檢查室和診所的採購更加複雜，促使一些服務提供者重新評估與供應商的關係和庫存策略。為此，製造商和經銷商正在探索本地組裝、採購管道多元化和價格調整等方案，以確保關鍵設備的供應。

將治療方法、產品類型、臨床最終用戶和分銷策略聯繫起來的細分市場洞察，以確定開發和商業化優先事項。

男性不孕症細分市場的趨勢揭示了不同的價值來源，這些價值來源指南著針對不同治療方法、產品類型、終端用戶和通路的產品開發和市場進入策略。根據治療類型，這些領域包括輔助生殖技術、生活方式和替代療法、藥物治療以及外科手術。輔助生殖技術本身包括卵胞漿內單一精子注射（ICSI）、子宮內人工授精（IUI）和體外受精（IVF），而生活方式和替代療法包括針灸、營養補充劑和體重管理。藥物治療包括抗生素療法、抗氧化療法和荷爾蒙療法，而外科手術包括睪丸切除術和輸精管吻合術。每個治療領域都有其獨特的臨床工作流程、報銷考量和證據收集需求，這些都會影響產品的上市時間。

北美、歐洲、中東和非洲以及亞太地區的區域趨勢和監管複雜性影響著我們的部署、製造和夥伴關係策略。

區域趨勢對男性不孕症產品和服務的臨床實踐標準、監管預期和商業性分銷管道產生顯著影響。在美洲，臨床應用趨勢和報銷機制正在推動結合診斷和輔助生殖技術的綜合性不孕症服務的發展。這種環境有利於對先進檢測設備和綜合診所級服務模式的投資。同時，該地區監管協調的努力正在塑造跨境供應商的策略，並為能夠提供可靠臨床和品質數據的供應商創造機會。

競爭格局分析揭示了成熟企業、專家創新者和策略夥伴關係關係如何推動男性不孕領域的差異化和臨床應用。

男性不孕領域的競爭格局涵蓋了成熟的醫療設備和診斷設備製造商、利基生物技術創新者、專注於臨床服務供應商以及新興的數位醫療公司。成熟的醫療設備和診斷設備製造商優先考慮可靠性、合規性和與實驗室資訊系統的整合，而新參與企業則傾向於專注於自動化、成本效益和數位分析，以實現產品差異化。臨床網路與技術開發商之間的策略合作日益普遍，雙方能夠共同進行檢驗研究和真實世界數據（REW）的開發，從而支持產品進入市場並被臨床醫生接受。

為行業領導者提供實用建議，以協調臨床證據、供應鏈韌性、以患者為中心的服務和通路策略，從而建立永續的競爭優勢。

產業領導者必須推動優先舉措，將臨床效用、商業性可行性和供應鏈韌性結合在一起。首先，透過有針對性的臨床試驗和真實世界數據 (RWD) 計劃加強證據生成，將增強臨床醫生對新型診斷和治療方法的信心，並使支付方和採購機構更清晰地了解其價值。其次，供應鏈多元化以及探索區域製造和組裝夥伴關係關係，將降低貿易政策變化帶來的風險，並確保關鍵醫療設備和耗材的持續供應。這些營運舉措必須輔以對品質系統和監管合規性的投資，以加速產品進入市場。

為了確保對男性不孕症的治療和商業化有透徹的了解，我們採用了嚴格的多方面調查方法，結合了臨床檢驗、監管審查和相關人員訪談。

本研究採用多方面、循證的調查方法，結合了同行評審文獻、監管文件、臨床指南以及對臨床醫生、檢查室管理人員和行業高管的訪談。此方法優先考慮將定量檢查室表現數據與對臨床決策、採購行為和監管解讀的定性見解進行三角驗證。檢驗程序包括將醫療設備規格與監管批准進行匹配，並將臨床工作流程與診斷中心、生育診所、醫院和學術研究機構的核准進行比對。

透過將臨床進展、營運挑戰和策略重點整合到簡潔的結論中，我們引導相關人員轉變男性不孕症治療的提供和商業化方式。

男性不孕症是一個複雜且不斷發展的領域，臨床創新、診斷技術的進步和不斷變化的商業性格局相互交織。基因和內分泌檢測的進步、輔助生殖技術的改進以及對整合式診療路徑日益重視，都提高了診斷的準確性並拓寬了治療選擇。同時，供應鏈中斷和貿易政策變化等營運壓力凸顯了製定具有韌性的籌資策略和立足本地的商業化計畫的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 男性不孕症市場（依治療方法分類）

  • 輔助生殖技術
    • ICSI
    • IUI
    • 體外受精（IVF）
  • 生活方式和替代療法
    • 針刺
    • 營養補充品
    • 體重管理
  • 藥物治療
    • 抗生素治療
    • 抗氧化療法
    • 荷爾蒙療法
  • 手術治療
    • 睪丸精子提取
    • 精索靜脈曲張切除術
    • 輸精管切除再吻合術

第9章：男性不孕症市場：依產品類型分類

  • 醫療設備
    • 離心機
    • 培養箱
    • 顯微鏡
  • 診斷藥物
    • 基因檢測
    • 荷爾蒙水平測試
    • 精液分析
  • 製藥
    • 抗生素
    • 抗氧化劑
    • 荷爾蒙
  • 補充
    • 胺基酸
    • 草藥萃取物
    • 維他命

第10章：男性不孕市場：依最終用戶分類

  • 診斷中心
  • 不孕症治療診所
  • 醫院
  • 研究機構

第11章 男性不孕症市場：依分銷管道分類

  • 直銷
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 男性不孕症市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 男性不孕市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 男性不孕症市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國男性不孕症市場

第16章：中國男性不孕市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer AG
  • Cook Medical LLC
  • Endo International plc
  • Ferring Arzneimittel AG
  • Hamilton Thorne Ltd
  • Merck KGaA
  • Roche Diagnostics International AG
  • Sun Pharmaceutical Industries Ltd
  • Thermo Fisher Scientific Inc
  • Vitrolife AB
Product Code: MRR-43286DA08074

The Male Infertility Market was valued at USD 4.42 billion in 2025 and is projected to grow to USD 4.79 billion in 2026, with a CAGR of 9.45%, reaching USD 8.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.42 billion
Estimated Year [2026] USD 4.79 billion
Forecast Year [2032] USD 8.33 billion
CAGR (%) 9.45%

A comprehensive introduction to the evolving clinical, technological, and policy dimensions shaping male infertility care and industry response across multiple care settings

Male infertility has evolved from a niche clinical concern into a multidisciplinary challenge that intersects reproductive medicine, diagnostics, device engineering, and public health policy. Advances in laboratory techniques, a deeper understanding of genetic and endocrine contributors, and growing patient awareness have elevated male factor infertility to a central consideration in fertility pathways. As clinicians and researchers refine diagnostic criteria and therapeutic approaches, industry stakeholders are recalibrating portfolios to address both acute clinical needs and long-term reproductive health outcomes.

Transitioning from historical perspectives, contemporary practice emphasizes integrated care that combines precision diagnostics with individualized treatment plans. The surge in assisted reproductive technologies has been paralleled by investments in semen analytics, genetic testing, and minimally invasive surgical techniques, creating opportunities for collaboration across clinical disciplines and commercial segments. Amid these shifts, regulatory frameworks and payer considerations continue to influence technology adoption and clinical trial design, underscoring the need for strategic alignment among innovators, clinicians, and policymakers.

How converging technological advances, patient-centered care models, and diagnostics-driven pathways are reshaping clinical practice and commercial strategy in male infertility

The landscape of male infertility care is undergoing transformative shifts driven by technological maturation, changing patient expectations, and a convergence of diagnostics and therapeutics. Precision diagnostics, including more accessible genetic testing and high-resolution semen analysis, are redefining diagnostic pathways and enabling tailored interventions. Simultaneously, the refinement of assisted reproductive procedures, such as intracytoplasmic sperm injection and targeted sperm retrieval techniques, has expanded options for couples where male factor issues are prominent.

Concurrently, non-conventional pathways are gaining traction: lifestyle and alternative therapies such as acupuncture, nutritional optimization, and structured weight management are increasingly integrated into preconception care plans. These shifts reflect broader health system priorities that favor holistic, patient-centered models and preventive strategies. On the commercial side, device miniaturization, improvements in laboratory automation, and the adoption of digital tools for remote monitoring have lowered barriers to scaling services, prompting new entrants and strategic partnerships. Taken together, these dynamics are reshaping clinical decision-making and accelerating the translation of research into practice.

Evaluating the cumulative operational and supply chain consequences of United States tariffs introduced in 2025 on devices, diagnostics, and therapeutic distribution within reproductive health

The introduction and implementation of tariffs in the United States in 2025 have introduced measurable friction into global supply chains that support reproductive health technologies, affecting manufacturers, distributors, and clinical service providers. Increased import costs for specialized equipment such as centrifuges, incubators, and precision microscopes can raise procurement complexity for laboratories and clinics, encouraging some providers to reassess supplier relationships and inventory strategies. In response, manufacturers and distributors have explored options including local assembly, diversified sourcing, and pricing adjustments to preserve access to essential instrumentation.

Beyond devices, tariffs can influence the availability and cost structure of diagnostics consumables and reagents used in genetic testing, hormone assays, and semen analysis. Those pressures have incentivized laboratory networks to optimize procurement cycles, invest in technical validation for alternative suppliers, and accelerate adoption of more efficient workflows that reduce per-test consumable use. Meanwhile, biopharmaceuticals and supplements that cross borders face shifted economics that may affect distribution channel strategies, with some vendors prioritizing direct sales or regional partnerships to mitigate tariff exposure. As a result, stakeholders are balancing near-term operational responses with longer-term strategic moves to shore up resilience against ongoing trade policy volatility.

Segment-focused insights linking treatment modalities, product typologies, clinical end users, and distribution strategies to prioritize development and commercialization pathways

Segment-level dynamics in male infertility reveal differentiated value drivers that inform product development and go-to-market strategies across treatment modalities, product types, end users, and distribution pathways. Based on treatment type, the landscape spans assisted reproductive technology, lifestyle and alternative therapies, medical therapy, and surgical procedures; assisted reproductive technology itself encompasses ICSI, IUI, and IVF, while lifestyle and alternative therapies include acupuncture, nutritional supplementation, and weight management, medical therapy incorporates antibiotic therapy, antioxidant therapy, and hormonal therapy, and surgical procedures comprise testicular sperm extraction, varicocelectomy, and vasovasostomy. Each of these treatment areas presents distinct clinical workflows, reimbursement considerations, and evidence generation needs that influence adoption timelines.

Based on product type, innovation and commercialization strategies must address devices, diagnostics, drugs, and supplements; within devices, the focus includes centrifuges, incubators, and microscopes, diagnostics cover genetic testing, hormone level testing, and semen analysis, drugs consist of antibiotic, antioxidant, and hormone classes, and supplements traverse amino acids, herbal extracts, and vitamins. Product design, regulatory pathways, and lab integration requirements differ markedly between capital equipment and point-of-care diagnostics, creating varied barriers to entry and collaboration opportunities. Based on end user, the market is served by diagnostic centers, fertility clinics, hospitals, and research institutes, each with unique procurement cycles, clinical expertise, and data integration needs. Based on distribution channel, organizations deploy direct sales, hospital pharmacies, online pharmacies, and retail pharmacies, and channel strategy influences margin structures, access to prescribers, and patient reach. Together, these intersecting segmentation lenses highlight where clinical demand, regulatory clarity, and commercial feasibility align to create priority opportunities for investment and partnership.

Regional dynamics and regulatory complexities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption, manufacturing, and partnership strategies

Regional dynamics exert considerable influence on clinical practice standards, regulatory expectations, and commercial pathways for male infertility products and services. In the Americas, clinical adoption trends and reimbursement structures favor integrated fertility services that combine diagnostics with assisted reproductive technologies; this environment supports investments in advanced laboratory instrumentation and comprehensive clinic-level service models. Meanwhile, regulatory harmonization efforts in the region shape cross-border supplier strategies and create opportunities for suppliers that can demonstrate robust clinical and quality data.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable healthcare funding models create a mosaic of adoption rates and clinical practices. Some European markets emphasize stringent diagnostic protocols and outcome reporting, whereas certain markets in the Middle East and Africa prioritize rapid capacity development and public-private partnerships to expand access. Across these jurisdictions, local manufacturing capacity and collaborative training programs influence procurement decisions. In Asia-Pacific, demographic shifts, rising awareness of fertility health, and expanding private healthcare sectors drive demand for both high-throughput diagnostics and point-of-care solutions. Rapidly developing clinical infrastructure and strong domestic manufacturing ecosystems encourage regionally tailored product designs and strategic alliances that accelerate commercialization timelines.

Competitive landscape analysis revealing how incumbents, specialized innovators, and strategic partnerships are driving differentiation and clinical adoption in male infertility

Competitive activity in male infertility spans long-established medical device and diagnostics firms, niche biotechnology innovators, clinically focused service providers, and emerging digital health entrants. Incumbent device and diagnostics companies emphasize reliability, regulatory compliance, and integration with laboratory information systems, whereas newer entrants frequently focus on automation, cost-efficiency, and digital analytics to differentiate their offerings. Strategic partnerships between clinical networks and technology developers are increasingly common, enabling co-development of validation studies and real-world evidence that support market access and clinician adoption.

At the same time, companies that combine diagnostic capabilities with therapeutic or service offerings gain advantages in end-to-end solutions, driving consolidation in certain segments. Smaller specialized firms often target unmet clinical needs with focused technologies such as advanced sperm selection, non-invasive genetic assays, or minimally invasive retrieval tools, and they frequently rely on licensing or strategic distribution agreements with larger players to scale. Across the competitive landscape, investment in clinical evidence, regulatory strategy, and post-market surveillance remains central to sustaining differentiation and supporting long-term adoption among clinicians and patients.

Actionable recommendations for industry leaders to align clinical evidence, supply chain resilience, patient-centered services, and channel strategies for durable competitive advantage

Industry leaders must pursue prioritized actions that align clinical utility with commercial viability and supply chain resilience. First, strengthening evidence generation through targeted clinical studies and real-world data initiatives will accelerate clinician confidence in new diagnostics and therapeutics and enable clearer value communication to payers and procurement bodies. Second, diversifying supply chains and considering regional manufacturing or assembly partnerships can mitigate exposure to trade policy shifts and ensure continuity of access to critical devices and consumables. These operational moves should be paired with investments in quality systems and regulatory readiness to speed market entry.

Third, organizations should adopt patient-centered service models that integrate lifestyle interventions, diagnostic precision, and coordinated referral pathways between diagnostic centers, fertility clinics, hospitals, and research institutes. Fourth, channel strategies must adapt: leveraging direct sales for institutional accounts while optimizing online and pharmacy partnerships to broaden patient access will balance reach with margin considerations. Finally, cultivating strategic alliances-whether through co-development, licensing, or clinical collaborations-will accelerate innovation, reduce time to validation, and distribute commercialization risk across complementary capabilities.

A rigorous multi-source research methodology combining clinical validation, regulatory review, and stakeholder interviews to ensure robust insights into male infertility care and commercialization

This research synthesis applied a multi-source, evidence-based methodology combining peer-reviewed literature, regulatory documentation, clinical guidelines, and primary interviews with clinicians, laboratory directors, and industry executives. The approach prioritized triangulation of quantitative laboratory performance data with qualitative insights on clinical decision-making, procurement behavior, and regulatory interpretation. Validation steps included cross-referencing device specifications with regulatory approvals, and corroborating clinical workflows with practicing specialists across diagnostic centers, fertility clinics, hospitals, and academic research institutes.

In addition, product-level analysis incorporated technical assessments of devices such as centrifuges, incubators, and microscopes, and evaluated diagnostic modalities including genetic testing, hormone level testing, and semen analysis against accepted clinical performance metrics. For therapeutic and supplement categories, the methodology emphasized mechanistic plausibility and clinical trial evidence where available, while recognizing the variable regulatory pathways that differentiate drugs, supplements, and complementary therapies. The research also examined distribution channel dynamics through interviews with procurement managers and channel partners, enabling a practical view of adoption barriers and facilitators across direct sales, hospital pharmacies, online pharmacies, and retail pharmacies.

Concise conclusion synthesizing clinical progress, operational challenges, and strategic priorities to guide stakeholders in transforming male infertility care delivery and commercialization

Male infertility represents a complex, evolving domain where clinical innovation, diagnostics advancement, and shifting commercial dynamics intersect. Progress in genetic and endocrine testing, refinements in assisted reproductive techniques, and growing emphasis on integrated care pathways have improved diagnostic clarity and expanded therapeutic choices. At the same time, operational pressures such as supply chain disruptions and evolving trade policy underscore the importance of resilient procurement strategies and regionalized commercialization plans.

Looking ahead, organizations that prioritize evidence-based innovation, form strategic partnerships across the value chain, and adapt distribution strategies to local realities will be best positioned to translate scientific progress into improved patient outcomes. By focusing on the alignment of clinical utility, regulatory compliance, and pragmatic channel execution, stakeholders can navigate the complexities of the landscape and help ensure that advances in male infertility care reach clinicians and patients efficiently and equitably.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Male Infertility Market, by Treatment Type

  • 8.1. Assisted Reproductive Technology
    • 8.1.1. ICSI
    • 8.1.2. IUI
    • 8.1.3. IVF
  • 8.2. Lifestyle And Alternative Therapies
    • 8.2.1. Acupuncture
    • 8.2.2. Nutritional Supplementation
    • 8.2.3. Weight Management
  • 8.3. Medical Therapy
    • 8.3.1. Antibiotic Therapy
    • 8.3.2. Antioxidant Therapy
    • 8.3.3. Hormonal Therapy
  • 8.4. Surgical Procedures
    • 8.4.1. Testicular Sperm Extraction
    • 8.4.2. Varicocelectomy
    • 8.4.3. Vasovasostomy

9. Male Infertility Market, by Product Type

  • 9.1. Devices
    • 9.1.1. Centrifuges
    • 9.1.2. Incubators
    • 9.1.3. Microscopes
  • 9.2. Diagnostics
    • 9.2.1. Genetic Testing
    • 9.2.2. Hormone Level Testing
    • 9.2.3. Semen Analysis
  • 9.3. Drugs
    • 9.3.1. Antibiotics
    • 9.3.2. Antioxidants
    • 9.3.3. Hormones
  • 9.4. Supplements
    • 9.4.1. Amino Acids
    • 9.4.2. Herbal Extracts
    • 9.4.3. Vitamins

10. Male Infertility Market, by End User

  • 10.1. Diagnostic Centers
  • 10.2. Fertility Clinics
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Male Infertility Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Male Infertility Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Male Infertility Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Male Infertility Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Male Infertility Market

16. China Male Infertility Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bayer AG
  • 17.6. Cook Medical LLC
  • 17.7. Endo International plc
  • 17.8. Ferring Arzneimittel AG
  • 17.9. Hamilton Thorne Ltd
  • 17.10. Merck KGaA
  • 17.11. Roche Diagnostics International AG
  • 17.12. Sun Pharmaceutical Industries Ltd
  • 17.13. Thermo Fisher Scientific Inc
  • 17.14. Vitrolife AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MALE INFERTILITY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MALE INFERTILITY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MALE INFERTILITY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MALE INFERTILITY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL MALE INFERTILITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. GCC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. GCC MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 257. GCC MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. GCC MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 259. GCC MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. GCC MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 261. GCC MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 262. GCC MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 264. GCC MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. GCC MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. G7 MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 293. G7 MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. G7 MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. G7 MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 296. G7 MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. G7 MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 298. G7 MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. G7 MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 300. G7 MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 301. G7 MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 302. G7 MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. G7 MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. NATO MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 306. NATO MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. NATO MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. NATO MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 309. NATO MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 310. NATO MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 311. NATO MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. NATO MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 313. NATO MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 314. NATO MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 315. NATO MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 316. NATO MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. NATO MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES MALE INFERTILITY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA MALE INFERTILITY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA MALE I